Literature DB >> 34180719

The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial.

G Adas1,2, Z Cukurova3, K Kart Yasar4, R Yilmaz3, N Isiksacan5, P Kasapoglu5, Z Yesilbag4, I D Koyuncu6,7, E Karaoz8,6,7.   

Abstract

The aim of this clinical trial was to control the cytokine storm by administering mesenchymal stem cells (MSCs) to critically-ill COVID-19 patients, to evaluate the healing effect, and to systematically investigate how the treatment works. Patients with moderate and critical COVID-19 clinical manifestations were separated as Group 1 (moderate cases, n = 10, treated conventionally), Group 2 (critical cases, n = 10, treated conventionally), and Group 3 (critical cases, n = 10, treated conventionally plus MSCs transplantation therapy of three consecutive doses on treatment days 0, 3, and 6, (as 3 × 106 cells/kg, intravenously). The treatment mechanism of action was investigated with evaluation markers of the cytokine storm, via biochemical parameters, levels of proinflammatory and anti-inflammatory cytokines, analyses of tissue regeneration via the levels of growth factors, apoptosis markers, chemokines, matrix metalloproteinases, and granzyme-B, and by the assessment of the immunomodulatory effects via total oxidant/antioxidant status markers and the levels of lymphocyte subsets. In the assessment of the overall mortality rates of all the cases, six patients in Group-2 and three patients in Group-3 died, and there was no loss in Group-1. Proinflammatory cytokines IFNγ, IL-6, IL-17A, IL-2, IL-12, anti-inflammatory cytokines IL-10, IL-13, IL-1ra, and growth factors TGF-β, VEGF, KGF, and NGF levels were found to be significant in Group-3. When Group-2 and Group-3 were compared, serum ferritin, fibrinogen and CRP levels in Group-3 had significantly decreased. CD45 +, CD3 +, CD4 +, CD8 +, CD19 +, HLA-DR +, and CD16 + / CD56 + levels were evaluated. In the statistical comparison of the groups, significance was only determined in respect of neutrophils. The results demonstrated the positive systematic and cellular effects of MSCs application on critically ill COVID-19 patients in a versatile way. This effect plays an important role in curing and reducing mortality in critically ill patients.

Entities:  

Keywords:  COVID-19; cytokines; growth factors; mesenchymal stem cell

Year:  2021        PMID: 34180719     DOI: 10.1177/09636897211024942

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  19 in total

Review 1.  Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application.

Authors:  Yunyu Zhao; Zhipeng Yan; Ying Liu; Yue Zhang; Jie Shi; Jingtao Li; Fanpu Ji
Journal:  Stem Cell Res Ther       Date:  2021-08-23       Impact factor: 6.832

2.  Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Wenchun Qu; Zhen Wang; Erica Engelberg-Cook; Dan Yan; Abu Bakar Siddik; Guojun Bu; Julie G Allickson; Eva Kubrova; Arnold I Caplan; Joshua M Hare; Camillo Ricordi; Carl J Pepine; Joanne Kurtzberg; Jorge M Pascual; Jorge M Mallea; Ricardo L Rodriguez; Tarek Nayfeh; Samer Saadi; Ravindra V Durvasula; Elaine M Richards; Keith March; Fred P Sanfilippo
Journal:  Stem Cells Transl Med       Date:  2022-07-20       Impact factor: 7.655

Review 3.  Stem cell-based therapy for human diseases.

Authors:  Duc M Hoang; Phuong T Pham; Trung Q Bach; Anh T L Ngo; Quyen T Nguyen; Trang T K Phan; Giang H Nguyen; Phuong T T Le; Van T Hoang; Nicholas R Forsyth; Michael Heke; Liem Thanh Nguyen
Journal:  Signal Transduct Target Ther       Date:  2022-08-06

Review 4.  Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis.

Authors:  Minghe Zhang; Xinchun Yan; Minghui Shi; Ruihang Li; Ziwei Pi; Xiangying Ren; Yongbo Wang; Siyu Yan; Yunyun Wang; Yinghui Jin; Xinghuan Wang
Journal:  Glob Health Res Policy       Date:  2022-06-23

5.  How to Make Sense out of 75,000 Mesenchymal Stromal Cell Publications?

Authors:  Dina Mönch; Marlies E J Reinders; Marc H Dahlke; Martin J Hoogduijn
Journal:  Cells       Date:  2022-04-22       Impact factor: 7.666

Review 6.  Immune-based therapeutic approaches in COVID-19.

Authors:  Aysan Moeinafshar; Niloufar Yazdanpanah; Nima Rezaei
Journal:  Biomed Pharmacother       Date:  2022-05-16       Impact factor: 7.419

7.  Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis.

Authors:  Weiqi Yao; Haibo Dong; Ji Qi; Yu Zhang; Lei Shi
Journal:  EClinicalMedicine       Date:  2022-07-09

8.  Clinical progress in MSC-based therapies for the management of severe COVID-19.

Authors:  Maria Rossello-Gelabert; Ainhoa Gonzalez-Pujana; Manoli Igartua; Edorta Santos-Vizcaino; Rosa Maria Hernandez
Journal:  Cytokine Growth Factor Rev       Date:  2022-07-06       Impact factor: 17.660

Review 9.  Mesenchymal stem cell therapy for COVID-19.

Authors:  Fatma Sengul; Bahadir Ozturk; Husamettin Vatansev
Journal:  Am J Stem Cells       Date:  2021-12-15

Review 10.  Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19.

Authors:  Kun Lu; Shi-Tao Geng; Shikai Tang; Hua Yang; Wei Xiong; Fang Xu; Qijun Yuan; Xian Xiao; Renqiang Huang; Haihui Liang; Zhipeng Chen; Chuanyun Qian; Yang Li; Songqing Wang
Journal:  Stem Cell Res Ther       Date:  2022-02-07       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.